

## 4-Bromo-*N*-(3,4,5-trimethoxyphenyl)benzamide

Na Xue,<sup>a</sup> Xiu-Yang Lu<sup>a</sup> and  
 Yong-Zhou Hu<sup>b\*</sup>

<sup>a</sup>Zhejiang University, Institute of Pharmaceutical Engineering, Department of Chemical and Biochemical Engineering, College of Materials Science and Chemical Engineering, Hangzhou 310027, Zhejiang, People's Republic of China, and <sup>b</sup>Zhejiang University, Department of Medicinal Chemistry, College of Pharmaceutical Science, Hangzhou 310031, Zhejiang, People's Republic of China

Correspondence e-mail:  
 huyz@zjuem.zju.edu.cn

### Key indicators

Single-crystal X-ray study  
 $T = 296$  K  
 Mean  $\sigma(\text{C}-\text{C}) = 0.006$  Å  
 Disorder in main residue  
 $R$  factor = 0.038  
 $wR$  factor = 0.090  
 Data-to-parameter ratio = 10.1


For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the molecule of the title compound,  $\text{C}_{16}\text{H}_{16}\text{BrNO}_4$ , the dihedral angle between the planes of the two rings is  $16.6(2)^\circ$ .

Received 1 March 2006  
 Accepted 20 April 2006

### Comment

Benzamide derivatives attract the attention of scientists for their widely known biological activities. They have been reported as arginine vasopressin receptor antagonists (Kakefuda *et al.*, 2002), dual acting agents with  $\alpha_1$ -adrenoceptor antagonistic action and steroid  $5\text{-}\alpha$  reductase inhibitory activity (Yoshida *et al.*, 1998), potassium channel activators (Biagi *et al.*, 2004) and anticancer agents (Cushman *et al.*, 1991). We were interested in benzamide derivatives on account of their antitumour activities. The title compound, (I), was chosen for crystallographic study in order to better understand its biological profile. The central carboxyl O atom is disordered over two sites (O11 and O12). The O11–C1 distance of  $1.251(10)$  Å suggests a double bond. The *N*-3,4,5-trimethoxyphenylformamide fragment is twisted from the mean plane of the 4-bromophenyl group by  $9.9(4)^\circ$ . The dihedral angle between the planes of the 3,4,5-trimethoxyaniline and 4-bromophenyl groups is  $16.6(2)^\circ$ .




### Experimental

The title compound was obtained from 3,4,5-trimethoxyaniline and *p*-bromobenzoyl chloride *via* the Schotten–Baumann reaction (Gao & Kawabatal, 2005). A crystal suitable for crystallographic study was obtained by slow crystallization from ethyl acetate at room temperature.

#### Crystal data

$\text{C}_{16}\text{H}_{16}\text{BrNO}_4$	$Z = 4$
$M_r = 366.21$	$D_x = 1.537$ Mg m <sup>-3</sup>
Orthorhombic, $P2_12_12_1$	Mo $K\alpha$ radiation
$a = 7.121(3)$ Å	$\mu = 2.62$ mm <sup>-1</sup>
$b = 8.492(3)$ Å	$T = 296(1)$ K
$c = 26.171(7)$ Å	Block, colourless
$V = 1582.6(9)$ Å <sup>3</sup>	$0.30 \times 0.30 \times 0.28$ mm



**Figure 1**

View of the molecule of the title compound, showing the atom-labeling scheme. Displacement ellipsoids are drawn at the 40% probability level and both disordered carboxyl oxygen atoms (O11 and O12) are shown.

#### Data collection

Rigaku R-Axis RAPID  
diffractometer  
 $\omega$  scans  
Absorption correction: multi-scan  
(*ABSCOR*; Higashi, 1995)  
 $T_{\min} = 0.456$ ,  $T_{\max} = 0.480$

15633 measured reflections  
2107 independent reflections  
1154 reflections with  $F^2 > 2\sigma(F^2)$   
 $R_{\text{int}} = 0.060$   
 $\theta_{\text{max}} = 27.5^\circ$

#### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.038$   
 $wR(F^2) = 0.090$   
 $S = 1.00$   
2107 reflections  
209 parameters  
H-atom parameters constrained

$w = 2/[1.09\sigma(F_o^2)]/(4F_o^2)$   
 $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 0.55 \text{ e } \text{\AA}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.51 \text{ e } \text{\AA}^{-3}$   
Extinction correction: Larson  
(1970), equation 22  
Extinction coefficient:  $1.7(3) \times 10^2$

The carboxyl O atom is disordered over two sites with equal occupancy. All H atoms were positioned geometrically. The methyl H atoms were then constrained to an ideal geometry with C–H distances of 0.96 Å and  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$ , but each group was allowed to rotate freely about its C–C bond. All other H atoms were placed in geometrically idealized positions and constrained to ride on their parent atoms with C–H distances of 0.93 Å, N–H = 0.84 Å and  $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C}, \text{N})$ . In the absence of significant anomalous scattering effects, Friedel pairs were averaged.

Data collection: *PROCESS-AUTO* (Rigaku/MSC, 2004); cell refinement: *PROCESS-AUTO*; data reduction: *CrystalStructure* (Rigaku/MSC, 2004); program(s) used to solve structure: *SIR97*; program(s) used to refine structure: *CRYSTALS* (Betteridge *et al.*, 2003); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997); software used to prepare material for publication: *CrystalStructure*.

The authors are grateful to Mr Jianmin Gu of the Analysis Centre of Zhejiang University.

#### References

- Betteridge, P. W., Carruthers, J. R., Cooper, R. L., Prout, K. & Watkin, D. J. (2003). *J. Appl. Cryst.* **36**, 1487.  
Biagi, G., Giorgi, I., Livi, O., Nardi, A., Calderone, V., Martelli, A., Martinotti, E. & Salerni, O. L. (2004). *Eur. J. Med. Chem.* **39**, 491–498.  
Cushman, M., Nagarathnam, D., Gopal, D., Chakraborti, A. K., Lin, C. M. & Hamel, E. (1991). *J. Med. Chem.* **34**, 2579–2588.  
Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.  
Gao, H. & Kawabatal, J. (2005). *Bioorg. Med. Chem. Lett.* **13**, 1661–1671.  
Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.  
Kakefuda, A., Tsukada, J., Kusayama, T., Tahara, A. & Tsukamoto, S. (2002). *Bioorg. Med. Chem. Lett.* **12**, 229–332.  
Larson, A. C. (1970). *Crystallographic Computing*, edited by F. R. Ahmed, pp. 291–294. Copenhagen: Munksgaard.  
Rigaku/MSC (2004). *PROCESS-AUTO* and *CrystalStructure* (Version 3.7.0). Rigaku/MSC, The Woodlands, Texas, USA.  
Yoshida, K., Horikoshi, Y., Eta, M., Chikazawa, J., Ogishima, M., Fukuda, Y. & Sato, H. (1998). *Bioorg. Med. Chem. Lett.* **8**, 2967–2972.